APOTEX APPEAL
COLD FEET IN CANADA
The Supreme Court of Canada was expected to bring the Canadian law on utility more into line with other jurisdictions, but those hopes have now received a setback, as Gunars Gaikis of Smart & Biggar/ Fetherstonhaugh reports.
O 26 Life Sciences Intellectual Property Review
n November 4, 2014, the Supreme Court of Canada was due to hear an appeal by generic drugs company
Apotex against a decision that found it to have infringed a patent covering the blockbuster drug Plavix (clopidogrel bisulfate). T e drug is a platelet aggregation inhibitor developed and marketed by Sanofi , as patentee, and Bristol- Myers Squibb (BMS), as licensee.
T e Supreme Court was widely expected to clarify and lower the utility requirement in Canadian patent law, which in recent years has
Volume 2, Issue 1
www.lifesciencesipreview.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44